Cargando…

Changes of natural killer cells’ phenotype in patients with chronic hepatitis B in intermittent interferon therapy

BACKGROUND: To investigate the changes of natural killer (NK) cell phenotype in the interferon alpha (IFN-α) treatment of chronic hepatitis B (CHB) and its relationship with clinical indicators. METHODS: The CHB patients who did not receive any antiviral treatment were set as initial treatment group...

Descripción completa

Detalles Bibliográficos
Autores principales: Bi, Xiaoyue, Xie, Si, Wu, Shuling, Cao, Weihua, Lin, Yanjie, Yang, Liu, Jiang, Tingting, Deng, Wen, Wang, Shiyu, Liu, Ruyu, Gao, Yuanjiao, Shen, Ge, Chang, Min, Hao, Hongxiao, Xu, Mengjiao, Chen, Xiaoxue, Hu, Leiping, Lu, Yao, Zhang, Lu, Xie, Yao, Li, Minghui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9922744/
https://www.ncbi.nlm.nih.gov/pubmed/36793722
http://dx.doi.org/10.3389/fimmu.2023.1116689
_version_ 1784887593108766720
author Bi, Xiaoyue
Xie, Si
Wu, Shuling
Cao, Weihua
Lin, Yanjie
Yang, Liu
Jiang, Tingting
Deng, Wen
Wang, Shiyu
Liu, Ruyu
Gao, Yuanjiao
Shen, Ge
Chang, Min
Hao, Hongxiao
Xu, Mengjiao
Chen, Xiaoxue
Hu, Leiping
Lu, Yao
Zhang, Lu
Xie, Yao
Li, Minghui
author_facet Bi, Xiaoyue
Xie, Si
Wu, Shuling
Cao, Weihua
Lin, Yanjie
Yang, Liu
Jiang, Tingting
Deng, Wen
Wang, Shiyu
Liu, Ruyu
Gao, Yuanjiao
Shen, Ge
Chang, Min
Hao, Hongxiao
Xu, Mengjiao
Chen, Xiaoxue
Hu, Leiping
Lu, Yao
Zhang, Lu
Xie, Yao
Li, Minghui
author_sort Bi, Xiaoyue
collection PubMed
description BACKGROUND: To investigate the changes of natural killer (NK) cell phenotype in the interferon alpha (IFN-α) treatment of chronic hepatitis B (CHB) and its relationship with clinical indicators. METHODS: The CHB patients who did not receive any antiviral treatment were set as initial treatment group and used pegylated interferon alpha (PEG-IFN α). Peripheral blood samples were collected at baseline, 4 weeks, and 12-24 weeks. For IFN-treated patients who entered the plateau were set as plateau group, and PEG-IFN α was discontinued and resumed after an interval of 12-24 weeks. Besides, we also enrolled some patients who had received oral drug for more than 6 months as oral drug group without follow up. Peripheral blood was collected during the plateau period, which was set as baseline, and after 12-24 weeks of intermittent treatment, and after 12-24 weeks of additional treatment with PEG-IFN α. The aim of the collection was to detect hepatitis B virus (HBV) virology, serology and biochemical indicators, and the NK cell related phenotype was detected by flow cytometry. RESULTS: In the plateau group, subgroup of CD69(+)CD56(dim) was higher with statistical significance when comparing with the initial treatment group and oral drug group [10.49 (5.27, 19.07) vs 5.03 (3.67, 8.58), Z = -3.11, P = 0.002; 10.49 (5.27, 19.07) vs 4.04 (1.90, 7.26), Z = -5.30, P < 0.001)]. CD57(+)CD56(dim) was significantly lower than that in initial treatment group and oral drug group respectively [68.42±10.37 vs 55.85±12.87, t = 5.84, P < 0.001; 76.38±9.49 vs 55.85±12.87, t = -9.65, P < 0.001]. The CD56(bright)CD16(-) subgroup in the plateau group was higher with statistical significance compared with initial treatment group and oral drug group respectively [11.64 (6.05, 19.61) vs 3.58 (1.94, 5.60), Z = -6.35, P < 0.001; 11.64 (6.05, 19.61) vs 2.37 (1.70, 4.30), Z = -7.74, P < 0.001)]. CD57(+)CD56(dim) in the plateau group had a significant higher percentage than that at baseline after IFN discontinuation for 12-24 weeks (55.85±12.87 vs 65.95±12.94, t = -2.78, P = 0.011). CONCLUSION: During the long-term treatment of IFN, the killer subgroup of NK cells is continuously depleted, leading to the differentiation of the regulatory subgroup into the killer subgroup. In the killing subgroup, although the number is continuously depleted, the activity of the subgroup is continuously increased. In the plateau phase, after stopping IFN for a period of time, the number of NK cell subsets would gradually recover, but was still lower than that in the initial treatment group.
format Online
Article
Text
id pubmed-9922744
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-99227442023-02-14 Changes of natural killer cells’ phenotype in patients with chronic hepatitis B in intermittent interferon therapy Bi, Xiaoyue Xie, Si Wu, Shuling Cao, Weihua Lin, Yanjie Yang, Liu Jiang, Tingting Deng, Wen Wang, Shiyu Liu, Ruyu Gao, Yuanjiao Shen, Ge Chang, Min Hao, Hongxiao Xu, Mengjiao Chen, Xiaoxue Hu, Leiping Lu, Yao Zhang, Lu Xie, Yao Li, Minghui Front Immunol Immunology BACKGROUND: To investigate the changes of natural killer (NK) cell phenotype in the interferon alpha (IFN-α) treatment of chronic hepatitis B (CHB) and its relationship with clinical indicators. METHODS: The CHB patients who did not receive any antiviral treatment were set as initial treatment group and used pegylated interferon alpha (PEG-IFN α). Peripheral blood samples were collected at baseline, 4 weeks, and 12-24 weeks. For IFN-treated patients who entered the plateau were set as plateau group, and PEG-IFN α was discontinued and resumed after an interval of 12-24 weeks. Besides, we also enrolled some patients who had received oral drug for more than 6 months as oral drug group without follow up. Peripheral blood was collected during the plateau period, which was set as baseline, and after 12-24 weeks of intermittent treatment, and after 12-24 weeks of additional treatment with PEG-IFN α. The aim of the collection was to detect hepatitis B virus (HBV) virology, serology and biochemical indicators, and the NK cell related phenotype was detected by flow cytometry. RESULTS: In the plateau group, subgroup of CD69(+)CD56(dim) was higher with statistical significance when comparing with the initial treatment group and oral drug group [10.49 (5.27, 19.07) vs 5.03 (3.67, 8.58), Z = -3.11, P = 0.002; 10.49 (5.27, 19.07) vs 4.04 (1.90, 7.26), Z = -5.30, P < 0.001)]. CD57(+)CD56(dim) was significantly lower than that in initial treatment group and oral drug group respectively [68.42±10.37 vs 55.85±12.87, t = 5.84, P < 0.001; 76.38±9.49 vs 55.85±12.87, t = -9.65, P < 0.001]. The CD56(bright)CD16(-) subgroup in the plateau group was higher with statistical significance compared with initial treatment group and oral drug group respectively [11.64 (6.05, 19.61) vs 3.58 (1.94, 5.60), Z = -6.35, P < 0.001; 11.64 (6.05, 19.61) vs 2.37 (1.70, 4.30), Z = -7.74, P < 0.001)]. CD57(+)CD56(dim) in the plateau group had a significant higher percentage than that at baseline after IFN discontinuation for 12-24 weeks (55.85±12.87 vs 65.95±12.94, t = -2.78, P = 0.011). CONCLUSION: During the long-term treatment of IFN, the killer subgroup of NK cells is continuously depleted, leading to the differentiation of the regulatory subgroup into the killer subgroup. In the killing subgroup, although the number is continuously depleted, the activity of the subgroup is continuously increased. In the plateau phase, after stopping IFN for a period of time, the number of NK cell subsets would gradually recover, but was still lower than that in the initial treatment group. Frontiers Media S.A. 2023-01-30 /pmc/articles/PMC9922744/ /pubmed/36793722 http://dx.doi.org/10.3389/fimmu.2023.1116689 Text en Copyright © 2023 Bi, Xie, Wu, Cao, Lin, Yang, Jiang, Deng, Wang, Liu, Gao, Shen, Chang, Hao, Xu, Chen, Hu, Lu, Zhang, Xie and Li https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Bi, Xiaoyue
Xie, Si
Wu, Shuling
Cao, Weihua
Lin, Yanjie
Yang, Liu
Jiang, Tingting
Deng, Wen
Wang, Shiyu
Liu, Ruyu
Gao, Yuanjiao
Shen, Ge
Chang, Min
Hao, Hongxiao
Xu, Mengjiao
Chen, Xiaoxue
Hu, Leiping
Lu, Yao
Zhang, Lu
Xie, Yao
Li, Minghui
Changes of natural killer cells’ phenotype in patients with chronic hepatitis B in intermittent interferon therapy
title Changes of natural killer cells’ phenotype in patients with chronic hepatitis B in intermittent interferon therapy
title_full Changes of natural killer cells’ phenotype in patients with chronic hepatitis B in intermittent interferon therapy
title_fullStr Changes of natural killer cells’ phenotype in patients with chronic hepatitis B in intermittent interferon therapy
title_full_unstemmed Changes of natural killer cells’ phenotype in patients with chronic hepatitis B in intermittent interferon therapy
title_short Changes of natural killer cells’ phenotype in patients with chronic hepatitis B in intermittent interferon therapy
title_sort changes of natural killer cells’ phenotype in patients with chronic hepatitis b in intermittent interferon therapy
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9922744/
https://www.ncbi.nlm.nih.gov/pubmed/36793722
http://dx.doi.org/10.3389/fimmu.2023.1116689
work_keys_str_mv AT bixiaoyue changesofnaturalkillercellsphenotypeinpatientswithchronichepatitisbinintermittentinterferontherapy
AT xiesi changesofnaturalkillercellsphenotypeinpatientswithchronichepatitisbinintermittentinterferontherapy
AT wushuling changesofnaturalkillercellsphenotypeinpatientswithchronichepatitisbinintermittentinterferontherapy
AT caoweihua changesofnaturalkillercellsphenotypeinpatientswithchronichepatitisbinintermittentinterferontherapy
AT linyanjie changesofnaturalkillercellsphenotypeinpatientswithchronichepatitisbinintermittentinterferontherapy
AT yangliu changesofnaturalkillercellsphenotypeinpatientswithchronichepatitisbinintermittentinterferontherapy
AT jiangtingting changesofnaturalkillercellsphenotypeinpatientswithchronichepatitisbinintermittentinterferontherapy
AT dengwen changesofnaturalkillercellsphenotypeinpatientswithchronichepatitisbinintermittentinterferontherapy
AT wangshiyu changesofnaturalkillercellsphenotypeinpatientswithchronichepatitisbinintermittentinterferontherapy
AT liuruyu changesofnaturalkillercellsphenotypeinpatientswithchronichepatitisbinintermittentinterferontherapy
AT gaoyuanjiao changesofnaturalkillercellsphenotypeinpatientswithchronichepatitisbinintermittentinterferontherapy
AT shenge changesofnaturalkillercellsphenotypeinpatientswithchronichepatitisbinintermittentinterferontherapy
AT changmin changesofnaturalkillercellsphenotypeinpatientswithchronichepatitisbinintermittentinterferontherapy
AT haohongxiao changesofnaturalkillercellsphenotypeinpatientswithchronichepatitisbinintermittentinterferontherapy
AT xumengjiao changesofnaturalkillercellsphenotypeinpatientswithchronichepatitisbinintermittentinterferontherapy
AT chenxiaoxue changesofnaturalkillercellsphenotypeinpatientswithchronichepatitisbinintermittentinterferontherapy
AT huleiping changesofnaturalkillercellsphenotypeinpatientswithchronichepatitisbinintermittentinterferontherapy
AT luyao changesofnaturalkillercellsphenotypeinpatientswithchronichepatitisbinintermittentinterferontherapy
AT zhanglu changesofnaturalkillercellsphenotypeinpatientswithchronichepatitisbinintermittentinterferontherapy
AT xieyao changesofnaturalkillercellsphenotypeinpatientswithchronichepatitisbinintermittentinterferontherapy
AT liminghui changesofnaturalkillercellsphenotypeinpatientswithchronichepatitisbinintermittentinterferontherapy